Winlevi is an anti-acne drug owned by Sun Pharm. It contains the active ingredient clascoterone and was first authorized for market use on 26 August, 2020. The drug comes in the form of a topical cream.

When will Winlevi generic be available?

The generic version of Winlevi is expected to become available after the expiration of the last patent on 25 July, 2030. This is also the earliest date a Para IV filing could be made against the drug.

Winlevi uses

Winlevi is primarily used for treating acne vulgaris. The active ingredient, clascoterone, is applied topically and helps in treating this skin condition.

Winlevi patent expiration

Winlevi holds a total of 8 patents, with none having expired as of now. The patent titled 'Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives' will expire last on 25 July, 2030. Winlevi generic could be available after this date. Below are the details of the patents:

Winlevi dosage

Want to ask something?